Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12

Journal of Virology

Volumn 71, Issue 10, 1997, Pages 7198-7206

  Mascola, John R ^a   Louder, Mark K ^b   Vancott, Thomas C ^b   Sapan, Christine V ^c   Lambert, John S ^d   Muenz, Larry R ^c   Bunow, Barry ^e   Birx, Deborah L ^a   Robb, Merlin L ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c NABI   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; DRUG POTENTIATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPROPHYLAXIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

EID: 0030823325     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.10.7198-7206.1997     Document Type: Article

References (75)

1. Allaway, G. P., A. M. Ryder, G. A. Beaudry, and P. J. Maddon. 1993. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res. Hum. Retroviruses 9:581-587.
2. Ashorn, P., B. Moss, J. N. Weinstein, V. K. Chaudhary, D. J. FitzGerald, I. Pastan, and E. A. Berger. 1990. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 87:8889-8893.
3. Bahmanyar, M., A. Fayaz, S. Nour-Salehi, M. Mohammadi, and H. Koprowski. 1976. Successful protection of humans exposed to rabies infection: postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 236:2751-2754.
4. Beasley, R. P., L. Y. Hwang, and C. E. Steven. 1983. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 3:135-141.
5. Buchacher, A., R. Predl, K. Strutzenberger, W. Steinfellner, A. Trkola, M. Purtscher, G. Gruber, C. Tauer, F. Steindl, A. Jungbauer, and H. Katinger. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS. Res. Hum. Retroviruses 10:359-369.
6. Buchbinder, A., S. Karwowska, M. K. Gorny, S. T. Burda, and S. Zolla-Pazner. 1992. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res. Hum. Retroviruses 8:425-427.
7. Bunow, B., and J. N. Weinstein. 1990. COMBO: a new approach to the analysis of drug combinations in vitro. Ann. N. Y. Acad. Sci. 616:490-494.
8. Burkly, L., N. Mulrey, R. Blumenthal, and D. S. Dimitrov. 1995. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoproteinmediated cell fusion and infection by an antibody to CD4 domain 2 in B combination with anti-gp120 antibodies. J. Virol. 69:4267-4273.
9. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharpe, G. B. Thornton, P. W. H. I. Parren, L. S. W. Sawyer, R. M. Hendry, N. Dunlop, P. Nara, M. Lamacchia, E. Garratty, E. R. Stiehm, Y. J. Bryson, Y. Cao, J. P. Moore, D. D. Ho, and C. F. Barbas, III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
10. Cao, J., L. Bergeron, E. Helseth, M. Thali, H. Repke, and J. Sodroski. 1993 Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 67:2747-2755.
11. Cavacini, L. A., J. Power, C. L. Emes, K. Mace, G. Treacy, and M. R. Posner, 1994. Plasma pharmacokinetics and biological activity of a human immunodeficiency virus type 1 neutralizing human monoclonal antibody, F105, in cynomolgus monkeys. J. Immunother. 15:251-255.
12. Centers for Disease Control. 1991. Vaccinia (smallpox) vaccine. Recommendations of the immunization practices advisory committee (ACIP). Morbid. Mortal. Weekly Rep. 40:1-10.
13. Chou, T.-C. and P. Talalay. 1977. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 252:6438-6442.
14. Conley, A. J., M. K. Gorny, J. A. Kessler II, L. J. Boots, M. Ossorio-Castro, S. Koenig, D. W. Lineberger, E. A. Emini, C. Williams, and S. Zolla-Pazner. 1994. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68:6994-7000.
15. Conley, A. J., J. A. Kessler II, L. J. Boots, P. M. McKenna, W. A. Schleif, E. A. Emini, G. E. Mark III, H. Katinger, E. K. Cobb, S. M. Lunceford, S. R. Rouse, and K. K. Murthy. 1996. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70:6751-6758.
16. Conley, A. J., J. A. Kessler II, L. J. Boots, J.-S. Tung, B. A. Arnold, P. M. Keller, A. R. Shaw, and E. A. Emini. 1994. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 91:3348-3352.
17. Cummins, L. M., K. J. Weinhold, T. J. Matthews, A. J. Langlois, C. F. Perno, R. M. Condie, and J.-P. Allain. 1991. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood 77:1111-1117.
18. Davis, D., D. M. Stephens, C. A. Carne, and P. J. Lachmann. 1993. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope. J. Gen. Virol. 74:2609-2617.
19. Delwart, E. L., E. G. Shpaer, J. Louwagie, F. E. McCutchan, M. Grez, H. Rübsamen-Waigmann, and J. I. Mullins. 1993. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 262:1257-1261.
20. D'Souza, M. P., G. Milman, J. A. Bradac, D. McPhee, C. V. Hanson, R. M. Hendry, T. Corcoran, J. Stott, M. Fung, C. Hanson, J. Laman, J. Mascola, S. Rasheed, D. Richman, H. Schuitemaker, C. Thiriart, M. Wainberg, J. Weber, S. Beddows, S. Tilley, J. Robinson, S. Zolla-Pazner, and H. Katinger. 1995. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 9:867-874.
21. Efron, B., and R. J. Tibshirani. 1993. An introduction to the bootstrap. Chapman and Hall, London, England.
22. Eichberg, J. W., K. K. Murthy, R. H. R. Ward, and A. M. Prince. 1992. Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG. AIDS Res. Hum. Retroviruses 8:1515.
23. Emanuel, D., I. Cunningham, K. Jules-Elysee, J. A. Brochstein, N. A. Kernan, J. Laver, D. Stover, D. A. White, A. Fels, B. Polsky, H. Castro-Malaspina, J. R. Peppard, P. Bartus, U. Hammerling, and R. J. O'Reilly. 1988. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann. Intern. Med. 109:777-782.
24. Emini, E. A., W. A. Schleif, J. H. Nunberg, A. J. Conley, Y. Eda, S. Tokiyoshi, S. D. Putney, S. Matsushita, K. E. Cobb, C. M. Jett, J. W. Eichberg, and K. K. Murthy. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-730.
25. Federer, WT. 1955. Experimental design: theory and application, p. 182-183. Macmillan, New York, N.Y.
26. Frickhofen, N., J. L. Abkowitz, M. Safford, M. Berry, J. Antunez-de-Mayolo, A. Astrow, R. Cohen, H. Halperin, L. King, D. Mintzer, B. Cohen, and N. S. Young. 1990. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann. Intern. Med. 113:926-933.
27. Gao, F., L. Yue, S. Craig, C. L. Thornton, D. L. Robertson, F. E. McCutchan, J. A. Bradac, P. M. Sharp, B. H. Hahn, and WHO Network for HIV Isolation and Characterization. 1994. Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. AIDS Res. Hum. Retroviruses 10:1359-1368.
28. Gellis, S. S., A. C. McGuinnes, and M. Peters. 1945. Study of prevention of mumps orchitis by gamma globulin. Am. J. Med. Sci. 210:661-664.
29. Gorny, M. K., J. P. Moore, A. J. Conley, S. Karwowska, J. Sodroski, C. Williams, S. Burda, L. J. Boots, and S. Zolla-Pazner. 1994. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. 68:8312-8320.
30. Groothius, J. R., E. A. F. Simoes, M. J. Levin, C. B. Hall, C. E. Long, W. J. Rodriguez, J. Arrobio, H. C. Meissner, D. R. Fulton, R. C. Welliver, D. A. Tristram, G. R. Siber, G. A. Prince, M. Van Raden, and V. G. Hemming. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N. Engl. J. Med. 329:1524-1530.
31. Gunthard, H. F., P. L. Gowland, J. Schupbach, M. S. C. Fung, J. Boni, R.-S. Liou, N. T. Chang, P. Grob, P. Graepel, D. G. Braun, and R. Luthy. 1994. A Phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. J. Infect. Dis. 170:1384-1393.
32. Hammon, W. M., L. L. Coriel, and P. F. Wehrle. 1953. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. JAMA 151:1272-1285.
33. Hinkula, J., G. Bratt, G. Gilljam, S. Nordlund, P. A. Broliden, V. Holmberg, E. Olausson-Hansson, J. Albert, E. Sandström, and B. Wahren. 1994. Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. J. Acquired Immune Defic. Syndr. 7:940-951.
34. Jackson, G. G., J. T. Perkins, M. Rubenis, D. A. Paul, M. Knigge, J. C. Despotes, and P. Spencer. 1988. Passive immunoneutralisation of human immunodeficiency virus in patients with advanced AIDS. Lancet 2:647-651.
35. Jacobson, J. M., N. Colman, N. A. Ostrow, R. W. Simson, D. Tomesch, L. Marlin, M. Rao, J. L. Mills, J. Clemens, and A. M. Prince. 1993. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J. Infect. Dis. 168:298-305.
36. Janeway, C. A. 1945. Use of concentrated human serum gamma-globulin in the prevention and treatment of measles. Bull. N. Y. Acad. Med. 21:202-220.
37. Japour, A. J., S. A. Fiscus, J.-M. Arduino, D. L. Mayers, P. S. Reichelderfer, and D. R. Kuritzkes. 1994. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J. Clin. Microbiol. 32:2291-2294.
38. Kalyanaraman, V. S., V. Rodriguez, F. Veronese, R. Rahman, P. Lusso, A. L. DeVico, T. Copeland, S. Oroszlan, R. C. Gallo, and M. G. Sarngadharan. 1990. Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 6:371-380.
39. Karpas, A., F. Hill, M. Youle, V. Cullen, J. Gray, N. Byron, F. Hayhoe, M. Tenant-Flowers, L. Howard, D. Gilgen, J. K. Oates, D. Hawkins, and B. Gazzard. 1988. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc. Natl. Acad. Sci. USA 85:9234-9237.
40. Kennedy, S. M., S. Orloff, C. C. Ibegbu, C. D. Odell, P. J. Maddon, and J. S. McDougal. 1991. Analysis of synergism/antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity. AIDS Res. Hum. Retroviruses 12:975-981.
41. Korns, R. F. 1952. Prevention of German measles with immune serum globulin. J. Infect. Dis. 90:183-189.
42. Krugman, S. 1963. The clinical use of gamma globulin. N. Engl. J. Med. 269:195-201.
43. Laal, S., S. Burda, M. K. Gorny, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1994. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J. Virol. 68:4001-4008.
44. Lambert, J. S., L. M. Mofenson, C. V. Fletcher, J. Moye, Jr., E. R. Stiehm, W. A. Meyer III, G. J. Nemo, B. J. Mathieson, G. Hirsch, C. V. Sapan, L. M. Cummins, E. Jimenez, E. O'Neil, A. Kovacs, and A. Stek. 1997. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. J. Infect. Dis. 175:283-291.
45. Levy, J., T. Youvan, and M. L. Lee. 1994. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. Blood 48:2130-2135.
46. Louwagie, J., W. Janssens, J. Mascola, L. Heyndrickx, P. Hegerich, G. van der Groen, F. E. McCutchan, and D. S. Burke. 1995. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J. Virol. 69:263-271.
47. Mascola, J. R., and D. S. Burke. 1993. Antigen detection in neutralization assays: high levels of interfering anti-p24 antibodies in some plasma. AIDS Res. Hum. Retroviruses 9:1173-1174. (Letter.)
48. Mascola, J. R., J. Louwagie, F. E. McCutchan, C. L. Fischer, P. A. Hegerich, K. F. Wagner, A. K. Fowler, J. G. McNeil, and D. S. Burke. 1994. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J. Infect. Dis. 169:48-54.
49. Mascola, J. R., S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, M. C. Keefer, M. J. McElrath, M. C. Walker, K. F. Wagner, J. G. McNeil, F. E. McCutchan, and D. S. Burke. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340-348.
50. McKeating, J. A., J. Cordell, C. J. Dean, and P. Balfe. 1992. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. Virology 191:732-742.
51. Montefiori, D. C., B. S. Graham, J. Zhou, R. A. Bucco, D. H. Schwartz, L. A. Cavacini, M. R. Posner, and NIH-NIAID AIDS Vaccine Clinical Trials Network. 1993. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. J. Clin. Invest. 92:840-847.
52. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Rüker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
53. Neurath, A. R., N. Strick, K. Lin, and S. Jiang. 1995. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions. AIDS Res. Hum. Retroviruses 11:687-696.
54. Osther, K., A. Wiik, F. Black, P. Skinhoj, K. Gottfried, K. E. Ugen, W. V. Williams, and D. B. Weiner. 1992. PASSHIV-1 treatment of patients with HIV-1 infection. A preliminary report of a phase I trial of hyperimmune porcine immunoglobulin to HIV-1. AIDS 6:1457-1464.
55. Potts, B. J., K. G. Field, Y. Wu, M. Posner, L. Cavacini, and M. White-Scharf. 1993. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies. Virology 197:415-419.
56. Prince, A. M., H. Reesink, D. Pascual, B. Horowitz, I. Hewlett, K. K. Murthy, K. E. Cobb, and J. W. Eichberg. 1991. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res. Hum. Retroviruses 7:971-973.
57. Ross, A. H. 1962. Modification of chicken pox in family contacts by administration of gamma globulin. N. Engl. J. Med. 267:369-376.
58. Sattentau, Q. J., S. Zolla-Pazner, and P. Poignard. 1995. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206:713-717.
59. Snydman, D. R., B. G. Werner, B. Heinze-Lacey, et al. 1987. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 317:1049-1054.
60. Stiehm, E. R., L. Mofenson, S. Zolla-Pazner, B. Jackson, N. L. Martin, A. J. Ammann, and Passive Antibody Workshop Participants. 1995. Summary of the workshop on passive immunotherapy in the prevention and treatment of HIV infection. Clin. Immunol. Immunopathol. 75:84-93.
61. Stokes, J., Jr., and J. R. Neefe. 1945. The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 127:144-145.
62. Szmuness, W., C. E. Stevens, E. J. Harley, et al. 1982. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N. Engl. J. Med. 307:1481-1486.
63. Thali, M., C. Furman, B. Wahren, M. Posner, D. D. Ho, J. Robinson, and J. Sodroski. 1992. Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J. Acquired Immune Defic. Syndr. 5:591-599.
64. Tilley, S. A., W. J. Honnen, M. E. Racho, T.-C. Chou, and A. Pinter. 1992. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res. Hum. Retroviruses 8:461-467.
65. Trkola, A., T. Dragic, J. Arthos, J. M. Binley, W. C. Olson, G. P. Allaway, C. Cheng-Mayer, J. Robinson, P. J. Maddon, and J. P. Moore. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187.
66. Trkola, A., A. B. Pomales, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway, H. Katinger, C. F. Barbas III, D. R. Burton, D. D. Ho, and J. P. Moore. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
67. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70: 1100-1108.
68. VanCott, T. C., F. R. Bethke, D. S. Burke, R. R. Redfield, and D. L. Birx. 1995. Lack of induction of antibodies specific for conserved discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. 155:4100-4110.
69. VanCott, T. C., F. R. Bethke, V. R. Polonis, M. K. Gorny, S. Zolla-Pazner, R. R. Redfield, and D. L. Birx. 1994. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J. Immunol. 153:449-459.
70. VanCott, T. C., L. D. Loomis, R. R. Redfield, and D. L. Birx. 1992. Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1. J. Immunol. Methods 146:163-176.
71. VanCott, T. C., S. C. D. Veit, V. Kalyanaraman, P. Earl, and D. L. Birx. 1995. Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen. J. Immunol. Methods 183:103-117.
72. Vijh-Warrier, S., A. Pinter, W. J. Honnen, and S. A. Tilley. 1996. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J. Virol. 70:4466-4473.
73. Vittecoq, D., B. Mattlinger, F. Barre-Sinoussi, A. M. Courouce, C. Rouzioux, C. Doinel, M. Bary, J. P. Viard, J. F. Bach, P. Rouger, and J. J. Lefrere. 1992. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J. Infect. Dis. 165:364-368.
74. Weinstein, J. N., B. Bunow, O. S. Weislow, R. F. Schinazi, S. M. Wahl, L. M. Wahl, and J. Szebeni. 1990. Synergistic drug combinations in AIDS therapy: dipyridamole/3′-azido-3′-deoxythymidine in particular and principles of analysis in general. Ann, N. Y. Acad. Sci. 616:367-384.
75. Wolfe, E. J., L. A. Cavacini, M. H. Samore, M. R. Posner, C. Kozial, C. Spino, C. B. Trapnell, N. Ketter, S. Hammer, and J. G. Gambertoglio. 1996. Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1. Clin. Pharmacol. Ther. 59:662-667.